Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 22:20:43时区推断·⟳ 抓取 22:21:41·⚡ 决策 07-29 22:22:25 +44s·89.9 天前
ViiV在AIDS 2026展示HIV长效注射治疗和预防数据
本次只是ViiV在学术会议展示既有长效HIV疗法的试验和真实世界数据，不是新获批、标签扩展、订单或业绩指引。
📄 原文Investing.com↗ 原文
ViiV Healthcare presents HIV treatment, prevention data at AIDS 2026
U.S. stocks open lower as rate-hike jitters, tech earnings gauntlet loom LONDON - ViiV Healthcare, the HIV specialist c…
不做 葛兰素史克（GSK.US）
会议数据更新方向偏正面但非监管获批或业绩指引，且未披露新增收入/利润量级；对大型药企GSK短线edge不足，不做。
不做 吉利德科学（GILD.US）
lenacapavir注射体验对比偏负面但不是销售下修、监管失败或核心产品商业化受阻，未达到做空或风险信号门槛，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 本次只是ViiV在学术会议展示既有长效HIV疗法的试验和真实世界数据，不是新获批、标签扩展、订单或业绩指引。
- GSK持有ViiV多数权益，但GSK为大型制药公司，未披露新增销售、利润或市场份额量化增量，短线市值级重定价依据不足。
- 对Gilead的lenacapavir仅有注射体验对比，不构成确认的商业损害或可执行做空催化。
主要风险
- 若后续出现监管批准、指南更新或公司给出Apretude/Cabenuva销售指引上修，需要作为新事件重新研判。
原文全文
展开原文 · 2,297 字
U.S. stocks open lower as rate-hike jitters, tech earnings gauntlet loom
LONDON - ViiV Healthcare, the HIV specialist company majority owned by GSK (LSE:GSK), presented data this week at the 26th International AIDS Conference in Rio de Janeiro covering its long-acting injectable HIV treatments and prevention therapies, according to a press release statement.
Week 96 results from the LATA trial showed cabotegravir plus rilpivirine dosed every two months was superior to daily oral therapy in 476 virologically suppressed adolescents aged 12 to 19 in Kenya, South Africa, Uganda and Zimbabwe. Confirmed viral rebound occurred in 0.9% of adolescents receiving the long-acting injection versus 6.4% receiving daily oral therapy. The study reported 94% of participants said long-acting injections were much easier to take than daily oral therapy.
Real-world data from the US-based OPERA cohort showed the long-acting injectable maintained virologic suppression comparable to daily oral therapy in nearly 6,800 virologically suppressed adults. At median follow-up of 15 months, 89% of individuals receiving the long-acting treatment had viral load below 50 copies/mL, compared with 83% receiving daily oral therapy at 22 months median follow-up.
The phase I CLARITY study compared injection experiences between cabotegravir and lenacapavir after single doses in 63 participants without HIV-1. Six-month follow-up data showed 70% rated the cabotegravir injection experience as very acceptable or totally acceptable, compared with 37% for lenacapavir. The study reported 90% of lenacapavir participants continued reporting nodules after six months, compared to 20% with cabotegravir.
The CAPTIVATE study found 97% of 190 participants with prior oral PrEP experience preferred cabotegravir for HIV prevention compared to daily oral options. The PrEPFACTS analysis of 2,913 people showed high adherence to cabotegravir dosing schedules, with 89% covered by PrEP for at least 90% of the measured period.
ViiV Healthcare also presented baseline data from the EXTEND 4M study evaluating an investigational cabotegravir formulation dosed three times yearly for HIV prevention in 229 participants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LONDON - ViiV Healthcare, the HIV specialist company majority owned by GSK (LSE:GSK), presented data this week at the 26th International AIDS Conference in Rio de Janeiro covering its long-acting injectable HIV treatments and prevention therapies, according to a press release statement.
Week 96 results from the LATA trial showed cabotegravir plus rilpivirine dosed every two months was superior to daily oral therapy in 476 virologically suppressed adolescents aged 12 to 19 in Kenya, South Africa, Uganda and Zimbabwe. Confirmed viral rebound occurred in 0.9% of adolescents receiving the long-acting injection versus 6.4% receiving daily oral therapy. The study reported 94% of participants said long-acting injections were much easier to take than daily oral therapy.
Real-world data from the US-based OPERA cohort showed the long-acting injectable maintained virologic suppression comparable to daily oral therapy in nearly 6,800 virologically suppressed adults. At median follow-up of 15 months, 89% of individuals receiving the long-acting treatment had viral load below 50 copies/mL, compared with 83% receiving daily oral therapy at 22 months median follow-up.
The phase I CLARITY study compared injection experiences between cabotegravir and lenacapavir after single doses in 63 participants without HIV-1. Six-month follow-up data showed 70% rated the cabotegravir injection experience as very acceptable or totally acceptable, compared with 37% for lenacapavir. The study reported 90% of lenacapavir participants continued reporting nodules after six months, compared to 20% with cabotegravir.
The CAPTIVATE study found 97% of 190 participants with prior oral PrEP experience preferred cabotegravir for HIV prevention compared to daily oral options. The PrEPFACTS analysis of 2,913 people showed high adherence to cabotegravir dosing schedules, with 89% covered by PrEP for at least 90% of the measured period.
ViiV Healthcare also presented baseline data from the EXTEND 4M study evaluating an investigational cabotegravir formulation dosed three times yearly for HIV prevention in 229 participants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。